|
1
|
Zhang Y, Ji Y, Liu S, Li J, Wu J, Jin Q,
Liu X, Duan H, Feng Z, Liu Y, et al: Global burden of female breast
cancer: New estimates in. 2022, temporal trend and future
projections up to 2050 based on the latest release from GLOBOCAN. J
Nat Cancer Center. 5:287–296. 2025.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Chotai N, Renganathan R, Uematsu T, Wang
J, Zhu Q, Rahmat K, Pradaranon V, Fong JC, Choridah L and Chang JM:
Breast cancer screening in Asian countries: Epidemiology, screening
practices, outcomes, challenges, and future directions. Korean J
Radio. 26:743–758. 2025.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wang F, Liu S, Li J, Shi Y, Geng Z, Ji Y
and Zheng J: Burdens of breast cancer and projections for 2030
Among Women in Asia: Findings from the 2021 global burden of
disease study. Curr Oncol. 32(267)2025.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Li C, Li Q, Mei Q and Lu T:
Pharmacological effects and pharmacokinetic properties of icariin,
the major bioactive component in Herba Epimedii. Life Sci.
126:57–68. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Wang N, Huang X, Wang X, Zhang Y, Wu R and
Shou D: Pipette tip solid-phase extraction and high-performance
liquid chromatography for the determination of flavonoids from
Epimedii herba in rat serum and application of the technique
to pharmacokinetic studies. J Chromatogr B. 990:64–72.
2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Cheng T, Zhang Y, Zhang T, Lu L, Ding Y
and Zhao Y: Comparative pharmacokinetics study of icariin and
icariside II in rats. Molecules. 20:21274–21286. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Zhang XW, Chen YP and Xia SX: LC-MS/MS
method for determination of icariin in healthy human plasma and
pharmacokinetic study. Liaoning J Tradit Chin Med. 41:133–135.
2014.(In Chinese).
|
|
8
|
Zou JM, Meng J, Yan ZH, Long ZX and Shi
XY: Pharmacokinetic studies of icariin in Chinese formulated
medicine. Chin Tradit Herb Drugs. 33:55–58. 2002.(In Chinese).
|
|
9
|
Indran IR, Liang RLZ, Min TE and Yong EL:
Preclinical studies and clinical evaluation of compounds from the
genus Epimedium for osteoporosis and bone health. Pharmacol Ther.
162:188–205. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Wu Y, Xia L, Zhou Y, Xu Y and Jiang X:
Icariin induces osteogenic differentiation of bone mesenchymal stem
cells in a MAPK-dependent manner. Cell Proliferat. 48:375–384.
2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Peng C, Liu Y, Heng YJ, Bodelon C, Stover
D, Chen WY, Holmes MD, Eliassen AH, Kraft P and Tamimi RM: The
impact of reproductive factors on breast tumor and normal-adjacent
tissue immune profile from menarche to menopause. Carcinogenesis.
46(bgaf 028)2025.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Osler TS, Schoeman M, Edge J, Pretorius
WJS, Rabe FH, Mathew CG and Urban MF: Breast cancer genetic
services in a South African Setting: Proband testing, cascading and
clinical management. Cancer Med. 14(e70743)2025.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Tan HL, Chan KG, Pusparajah P, Saokaew S,
Duangjai A, Lee LH and Goh BH: Anti-cancer properties of the
naturally occurring aphrodisiacs: Icariin and its derivatives.
Front Pharmacol. 7(191)2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Sharaky M, El Kiki SM, Effat H and Mansour
HH: Effect of palliative radiotherapy and cyclin-dependent kinase
4/6 inhibitor on breast cancer cell lines. Naunyn Schmiedebergs
Arch Pharmacol. 398:10753–10768. 2025.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Noyan S and Dedeoğlu BG: Upregulation of
miR-99b-5p Modulates ESR1 expression as an adaptive mechanism to
circumvent drug response via facilitating ER/HER2 crosstalk. Balkan
Med J. 42:150–156. 2025.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Wang L, Zhang M, Zhao K, Yuan X, Zhao H,
Liu Y, Ji Y and Lu P: The role of ESRP1 in solid tumor development
through the regulation of CD44 splicing and EMT processes. Front
Oncol. 15(1451130)2025.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Li J, Wu Z, Pan Y, Chen Y, Chu J, Cong Y
and Fang Q: GNL3L exhibits pro-tumor activities via NF-κB pathway
as a poor prognostic factor in acute myeloid leukemia. J Cancer.
15:4072–4080. 2024.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ran XJ and Yu XD: Research progress of
natural active ingredients against breast cancer. Hans J Med Chem.
12:68–76. 2024.(In Chinese).
|
|
19
|
Song L, Chen X, Mi L, Liu C, Zhu S, Yang
T, Luo X, Zhang Q, Lu H and Liang X: Icariin-induced inhibition of
SIRT6/NF-κB triggers redox mediated apoptosis and enhances
anti-tumor immunity in triple-negative breast cancer. Cancer Sci.
111:4242–4256. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Cheng X, Tan S, Duan F, Yuan Q, Li Q and
Deng G: Icariin induces apoptosis by suppressing autophagy in
tamoxifen-resistant breast cancer cell line MCF-7/TAM. Breast
Cancer. 26:766–775. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Song B, Wei F, Peng J, Wei X, Liu M, Nie
Z, Ma Y and Peng T: Icariin regulates EMT and Stem Cell-like
character in breast cancer through modulating lncRNA
NEAT1/TGFβ/SMAD2 signaling pathway. Biol Pharm Bull. 47:399–410.
2024.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Song B, Liu MR, Wei FX, Chen Y, Di SS,
Zhai CT, Ma YM and Peng T: Epimedium regulates stem cell-like
character of breast cancer via miR-148a. Chin Pharmacol Bull.
39:851–859. 2023.(In Chinese).
|
|
23
|
Kim B, Lee KY and Park B: Icariin
abrogates osteoclast formation through the regulation of the
RANKL-mediated TRAF6/NF-κB/ERK signaling pathway in Raw264. 7
cells. Phytomedicine. 51:181–190. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wang W, Zhang X, Gao S, Liu J, Jiang S,
Meng Q, Zhang H, Li Y, Shi W and Lv Y: Icariin inhibits autophagy
and promotes apoptosis by regulating mitochondrial division in
Triple-negative breast cancer. Biochem Pharmacol.
243(117549)2026.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Xiao ZY, Yang ZA, Chen CH, Li J, He Y, Fu
P and Wang J: Icariin inhibits the migration and invasion of triple
negative breast cancer by down-regulating the TFG-β/Smad signaling
pathway. Acta Univ Med Anhui. 60:1574–1582. 2025.(In Chinese).
|
|
26
|
Guo Y, Zhang X, Meng J and Wang ZY: An
anticancer agent icaritin induces sustained activation of the
extracellular signal-regulated kinase (ERK) pathway and inhibits
growth of breast cancer cells. Eur J Pharmacol. 658:114–122.
2011.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wang Z, Wang D, Yang D, Zhen W, Zhang J
and Peng S: The effect of icariin on bone metabolism and its
potential clinical application. Osteoporosis Int. 29:535–544.
2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Wang Z, Zhang H, Dai L, Song T, Li P, Liu
Y and Wang L: Arsenic trioxide and icariin show synergistic
anti-leukemic activity. Cell Biochem Biophy. 73:213–219.
2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Xiao H, Wignall N and Brown ES: An
open-label pilot study of icariin for co-morbid bipolar and alcohol
use disorder. Am J Drug Alcohol Abuse. 42:162–167. 2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Dongye Z, Wu X, Wen Y, Ding X, Wang C,
Zhao T, Li J and Wu Y: Icaritin and intratumoral injection of CpG
treatment synergistically promote T cell infiltration and antitumor
immune response in mice. Int Immunopharm.
111(109093)2022.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Li B, Lau LY and Chen Y: Linking FAM111B
to metabolic-immune remodeling in breast ductal carcinoma. J Transl
Med. 24(177)2026.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Liu M, Wang B, Guo C, Hou X, Cheng Z and
Chen D: Novel multifunctional triple folic acid, biotin and CD44
targeting pH-sensitive Nano-actiniaes for breast cancer
combinational therapy. Drug Deliv. 26:1002–1016. 2019.PubMed/NCBI View Article : Google Scholar
|
